Should I buy or sell Taro Pharmaceutical Industries stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TARO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TARO, but not buy additional shares or sell existing shares. View TARO analyst ratings or view top-rated stocks .

What is Taro Pharmaceutical Industries' stock price target for 2024?

1 Wall Street research analysts have issued 1 year price objectives for Taro Pharmaceutical Industries' stock. Their TARO share price targets range from $43.00 to $43.00. On average, they expect the company's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 1.7% from the stock's current price. View analysts price targets for TARO or view top-rated stocks among Wall Street analysts .

How have TARO shares performed in 2024?

Taro Pharmaceutical Industries' stock was trading at $41.78 on January 1st, 2024. Since then, TARO stock has increased by 1.2% and is now trading at $42.2750. View the best growth stocks for 2024 here .

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a decline in short interest in March. As of March 31st, there was short interest totaling 39,800 shares, a decline of 32.0% from the March 15th total of 58,500 shares. Based on an average daily volume of 51,900 shares, the short-interest ratio is presently 0.8 days. Approximately 0.5% of the company's stock are short sold. View Taro Pharmaceutical Industries' Short Interest .

When is Taro Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024. View our TARO earnings forecast .

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its earnings results on Thursday, January, 25th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.30 by $0.26. The company earned $157.15 million during the quarter, compared to analysts' expectations of $154.90 million. Taro Pharmaceutical Industries had a net margin of 7.48% and a trailing twelve-month return on equity of 3.26%.

What ETF holds Taro Pharmaceutical Industries' stock?

ARK Israel Innovative Technology ETF holds 50,932 shares of TARO stock, representing 1.98% of its portfolio.

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com . Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD) , Bausch Health Companies (BHC) , Broadcom (AVGO) , Pfizer (PFE) , Teva Pharmaceutical Industries (TEVA) , Skyworks Solutions (SWKS) , GW Pharmaceuticals (GWPH) , Delta Air Lines (DAL) , Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV) .

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Free TARO Stock Alerts

$42.28

+0.23 (+0.55%)

(As of 04/17/2024 ET)

Compare

Today's Range: $42.14
▼
$42.48
50-Day Range: $40.96
▼
$42.40
52-Week Range: $24.22
▼
$45.76

Volume: 15,038 shs
Average Volume: 26,199 shs
Market Capitalization: $1.59 billion

P/E Ratio: 34.65
Dividend Yield: N/A
Price Target: $43.00

Get Taro Pharmaceutical Industries alerts:

Taro Pharmaceutical Industries MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 1.7% Upside
$43.00 Price Target
Short Interest: Healthy
0.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.55
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

Medical Sector

680th out of 913 stocks

Pharmaceutical Preparations Industry

292nd out of 396 stocks

1.0

Analyst's Opinion

Consensus Rating
Taro Pharmaceutical Industries has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Taro Pharmaceutical Industries has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.49% of the float of Taro Pharmaceutical Industries has been sold short.
Short Interest Ratio / Days to Cover
Taro Pharmaceutical Industries has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Taro Pharmaceutical Industries has recently decreased by 31.97%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Taro Pharmaceutical Industries does not currently pay a dividend.
Dividend Growth
Taro Pharmaceutical Industries does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TARO.

2.5

News and Social Media Coverage

News Sentiment
Taro Pharmaceutical Industries has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Taro Pharmaceutical Industries this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Taro Pharmaceutical Industries insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.80% of the stock of Taro Pharmaceutical Industries is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.40% of the stock of Taro Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Taro Pharmaceutical Industries is 34.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.98.
Price to Earnings Ratio vs. Sector
The P/E ratio of Taro Pharmaceutical Industries is 34.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 270.63.
Price to Book Value per Share Ratio
Taro Pharmaceutical Industries has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About Taro Pharmaceutical Industries Stock (NYSE:TARO)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

TARO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TARO Stock News Headlines

April 17, 2024 | morningstar.com

Taro Pharmaceutical Industries Ltd TAL

April 15, 2024 | stocknews.com

JNJ Earnings Forecast - Is Pharmaceutical Industry Set for Shake-up?

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

April 15, 2024 | businesswire.com

Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.

April 11, 2024 | americanbankingnews.com

Taro Pharmaceutical Industries (NYSE:TARO) Stock Price Passes Above 200 Day Moving Average of $39.61

April 11, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Taro Pharmaceutical Industries (NYSE:TARO)

March 28, 2024 | finance.yahoo.com

Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children with the Introduction of bébé Bottoms™ Diaper Rash Crème Spray

March 27, 2024 | finance.yahoo.com

Taro Pharmaceutical Industries Ltd. (TARO)

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

March 22, 2024 | morningstar.com

Taro Pharmaceutical Industries Ltd

March 13, 2024 | finanznachrichten.de

Crescita Therapeutics Inc. Reports Q4 and Fiscal 2023 Results

March 11, 2024 | msn.com

Sun Pharma initiates recall of Febuxostat for gout in US

March 6, 2024 | finance.yahoo.com

Taro Expands Branded Over-the-Counter Portfolio in U.S. with the Launch of FeverAll® Liquid Oral Acetaminophen for Children Ages 2-11

February 24, 2024 | msn.com

Taro Pharmaceutical Industries (TARO) Price Target Increased by 22.86% to 43.86

February 15, 2024 | finance.yahoo.com

Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)

February 7, 2024 | msn.com

JB Chemicals & Pharma Q3 results: Net profit rises 26% to Rs 134 crore

February 7, 2024 | businesswire.com

TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro ...

January 30, 2024 | finance.yahoo.com

Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro

January 25, 2024 | finance.yahoo.com

Taro Provides Results for December 31, 2023

January 19, 2024 | msn.com

Sun Pharma to acquire remaining 21.52% shares of Taro for Rs 2,891.76 crore

January 18, 2024 | msn.com

Sun Pharma to acquire Taro shares for $347.73m

January 18, 2024 | msn.com

India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 mln

January 17, 2024 | tmcnet.com

TARO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Taro Pharmaceutical Industries Ltd. Is Fair to Shareholders

January 17, 2024 | markets.businessinsider.com

Sun Pharma To Acquire Taro Pharma For US$43.00/shr In Cash

January 17, 2024 | sg.finance.yahoo.com

India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 million

January 17, 2024 | marketwatch.com

Sun Pharmaceutical to Take Taro Private at $43/Shr

January 17, 2024 | msn.com

Sun Pharma to take Taro private for $43 per share

See More Headlines

Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/25/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/28/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:TARO
CUSIP: N/A
CIK: 906338
Web: www.taro.com
Phone: (724) 847-5700
Fax: 914-345-6169
Employees: 1,554
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $43.00
High Stock Price Target: $43.00
Low Stock Price Target: $43.00
Potential Upside/Downside: +1.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.22
Trailing P/E Ratio: 34.65
Forward P/E Ratio: 30.63
P/E Growth: N/A
Net Income: $25.44 million
Net Margins: 7.48%
Pretax Margin: 12.17%
Return on Equity: 3.26%
Return on Assets: 2.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.60
Quick Ratio: 3.03

Sales & Book Value

Annual Sales: $572.95 million
Price / Sales: 2.77
Cash Flow: $1.76 per share
Price / Cash Flow: 24.04
Book Value: $46.05 per share
Price / Book: 0.92

Miscellaneous

Outstanding Shares: 37,590,000
Free Float: 32,400,000
Market Cap: $1.59 billion
Optionable: Optionable
Beta: 0.61

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Uday V. Baldota (Age 54)
CEO & Director
Mr. William J. Coote (Age 69)
VP, CFO & Chief Accounting Officer
Mr. Itamar Karsenti (Age 52)
VP & Head of Operations
Mr. Avi Avramoff (Age 59)
VP and Head of R&D
Mr. Itzik Baruch (Age 61)
Vice President of Technical Services
Dr. Roman Kaplan (Age 77)
Vice President of Scientific and Technical Compliance Manager
Mr. Erik Zwicker J.D. (Age 44)
VP, General Counsel & Secretary
Mr. Ara Aprahamian (Age 56)
Vice President of Sales & Marketing
Comp: $616.14k
Ms. Michele Visosky (Age 58)
VP & Head of Human Resource
Mr. Jayesh Shah (Age 68)
Head of Procurement

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TARO Stock Analysis - Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TARO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TARO, but not buy additional shares or sell existing shares.
View TARO analyst ratings or view top-rated stocks.
What is Taro Pharmaceutical Industries' stock price target for 2024?: 1 Wall Street research analysts have issued 1 year price objectives for Taro Pharmaceutical Industries' stock. Their TARO share price targets range from $43.00 to $43.00. On average, they expect the company's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 1.7% from the stock's current price.
View analysts price targets for TARO or view top-rated stocks among Wall Street analysts.
How have TARO shares performed in 2024?: Taro Pharmaceutical Industries' stock was trading at $41.78 on January 1st, 2024. Since then, TARO stock has increased by 1.2% and is now trading at $42.2750.
View the best growth stocks for 2024 here.
Are investors shorting Taro Pharmaceutical Industries?: Taro Pharmaceutical Industries saw a decline in short interest in March. As of March 31st, there was short interest totaling 39,800 shares, a decline of 32.0% from the March 15th total of 58,500 shares. Based on an average daily volume of 51,900 shares, the short-interest ratio is presently 0.8 days. Approximately 0.5% of the company's stock are short sold.
View Taro Pharmaceutical Industries' Short Interest.
When is Taro Pharmaceutical Industries' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our TARO earnings forecast.
How were Taro Pharmaceutical Industries' earnings last quarter?: Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its earnings results on Thursday, January, 25th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.30 by $0.26. The company earned $157.15 million during the quarter, compared to analysts' expectations of $154.90 million. Taro Pharmaceutical Industries had a net margin of 7.48% and a trailing twelve-month return on equity of 3.26%.

What ETF holds Taro Pharmaceutical Industries' stock?: ARK Israel Innovative Technology ETF holds 50,932 shares of TARO stock, representing 1.98% of its portfolio.
What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?: 11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Taro Pharmaceutical Industries own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).
How do I buy shares of Taro Pharmaceutical Industries?: Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:TARO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Taro Pharmaceutical Industries (TARO) Stock Price, News & Analysis

Taro Pharmaceutical Industries MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Taro Pharmaceutical Industries Stock (NYSE:TARO)

TARO Stock Price History

TARO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

TARO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™